Breast-conserving treatment for ductal carcinoma in situ: Impact of boost and tamoxifen on local recurrences
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Breast-conserving treatment for ductal carcinoma in situ: Impact of boost and tamoxifen on local recurrences |
| Type de publication | Journal Article |
| Year of Publication | 2016 |
| Auteurs | Cutuli B., Wiezzane N., Palumbo I., Barbieri P., Guenzi M., Huscher A., Borghesi S., Delva C., Iannone T., Vianello E., Rosetto M.-E, Aristei C. |
| Journal | CANCER RADIOTHERAPIE |
| Volume | 20 |
| Pagination | 292-298 |
| Date Published | JUN |
| Type of Article | Article |
| ISSN | 1278-3218 |
| Mots-clés | Boost, Breast-conserving therapy, DCIS, local recurrence, Nuclear grade, Tamoxifen, treatment |
| Résumé | {Purpose. - Ductal carcinoma in situ represents 15 to 20% of all breast cancers. Breast-conserving surgery and whole breast irradiation was performed in about 60% of the cases. This study reports local recurrence rates in patients with ductal carcinoma in situ treated by breast-conserving surgery and whole breast irradiation with or without boost and/or tamoxifen and compares different therapeutic options in two European countries. Patients and methods. - From 1998 to 2007, 819 patients with pure ductal carcinoma in situ were collected, both in France (266) and Italy (553). Median age was 56. All underwent breast-conserving surgery and whole breast irradiation; 391 (48%) received a boost (55% in France and 45% in Italy |
| DOI | 10.1016/j.canrad.2016.04.004 |